Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 8/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4740651 | 0.85 | LOXL2 (0.68) | RHEBDAOTDP1LOXL2SIRT1 | |
| SCHEMBL13624442 | 0.81 | ALOX15 (0.50) | DAOLOXL2ALOX15SIRT1F11 | |
| SCHEMBL6989136 | 0.78 | DAO (0.49) | RHEBDAOLOXL2ALOX15SIRT1 | |
| SCHEMBL13544012 | 0.77 | RAD52 (0.41) | RHEBTDP1LOXL2 | |
| SCHEMBL30811732 | 0.77 | AHR (0.42) | RHEBLOXL2 | |
| SCHEMBL9929376 | 0.77 | AHR (0.42) | RHEBLOXL2 | |
| SCHEMBL5795144 | 0.77 | DAO (0.51) | RHEBDAO | |
| SCHEMBL14758215 | 0.77 | RHEB (0.39) | RHEBLOXL2 | |
| SCHEMBL25505982 | 0.77 | MAPT (0.53) | DAOLOXL2 | |
| SCHEMBL7014953 | 0.76 | DAO (0.44) | DAOTDP1LOXL2ALOX15SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107973791-B | Fused or tricyclic aryl pyrimidine compounds as kinase inhibitors | 南京圣和药业股份有限公司 | 2020-04-07 | — | — | CN | disclosed |
| CN-107614503-B | Fused or tricyclic aryl pyrimidine compounds as kinase inhibitors | 广东众生药业股份有限公司 | 2020-03-10 | — | — | CN | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3290419-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-08-07 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| EP-3312179-B1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | NANJING SANHOME PHARMACEUTICAL CO LTD (CN) | 2019-07-10 | — | — | EP | disclosed |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-12-13 | — | — | US | disclosed |
| US-10093656-B2 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | NANJING SANHOME PHARMACEUTICAL CO., LTD (CN) | 2018-10-09 | — | — | US | disclosed |
| EP-3312179-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-25 | — | — | EP | disclosed |
| EP-3312179-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-25 | — | — | EP | disclosed |
| US-20060014759-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2006-01-19 | — | — | US | disclosed |
| CN-1617855-A | Cytosolic phospholipase A2Inhibitors | WYETH CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| US-6797708-B2 | ENZYME INHIBITORS SUCH AS 4-(2-(1-BENZHYDRYL-2-(2-((BENZYL-SULFONYL)AMINO)ETHYL)-5-CHLORO-1H-INDOL-3 -YL)ETHOXY) BENZOIC ACID, USED AS ANALGESICS OR ANTIINFLAMMATORY AGENTS | WYETH | 2004-09-28 | — | — | US | disclosed |
| EP-1451154-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6635771-B2 | Useful as intermediates in the synthesis of compounds having activity as chemical inhibitors of various phospholipase enzymes, particularly phospholipase A2 | WYETH | 2003-10-21 | — | — | US | disclosed |
| US-20030166649-A1 | Methods for treating arthritic disorders | WYETH | 2003-09-04 | — | — | US | disclosed |
| US-20030158405-A1 | Chemical intermediates for making a phospholipase enzyme inhibitors | WYETH | 2003-08-21 | — | — | US | disclosed |
| US-20030149029-A1 | Methods for treating asthmatic conditions | WYETH | 2003-08-07 | — | — | US | disclosed |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH | 2003-07-31 | — | — | US | disclosed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093656-B2 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor | EGFR, ERBB2, ERBB4 | RHEB 1642/4885DAO 988/4885TDP1 2278/4885 |
| US-20030158405-A1 | Chemical intermediates for making a phospholipase enzyme inhibitors | PLA2R1, PLD1, PLA2G1B | RHEB 2399/4885DAO 1197/4885TDP1 611/4885 |
| US-20180354953-A1 | FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | RHEB 1642/4885DAO 988/4885TDP1 2278/4885 |
| US-20030166649-A1 | Methods for treating arthritic disorders | PLA2G12A, PLA2G4A, PLA2G4B | RHEB 2863/4885DAO 430/4885TDP1 1051/4885 |
| US-20060014759-A1 | Methods for the use of inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G1B | RHEB 2358/4885DAO 689/4885TDP1 1810/4885 |
| US-20030149029-A1 | Methods for treating asthmatic conditions | PLA2G4A, PLA2G4B, PLA2G1B | RHEB 3155/4885DAO 906/4885TDP1 1987/4885 |
| US-20030144282-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4A, PLA2G4B, PLA2G4C | RHEB 2703/4885DAO 1176/4885TDP1 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.